Insider · CIK 0001823925
Tom Frohlich
Files at JBIO (Jade Biosciences, Inc.). First filing May 19, 2025, latest May 19, 2025.
Tom Frohlich files SEC Form 4 as CEO and director at JBIO (Jade Biosciences, Inc.). Since May 19, 2025, Tom Frohlich has reported 1 open-market buy worth $44k and 0 open-market sells worth $0, the latest filed on May 19, 2025.
A track record needs three past buys with six months of prices behind them; Tom Frohlich has 0, so none is measured yet.
The newest scored trade: bought $44k of JBIO on May 16, 2025, filed May 19, 2025, scored 39 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
JBIO: Jade Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | JBIO Jade Biosciences, Inc. | AGrant or award Common Stock | +78,750 | $0.00 | $0 | 86,331 | Feb 13, 2026 |
| Feb 12, 2026 | JBIO Jade Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +472,500 | $0.00 | $0 | 472,500 | Feb 13, 2026 |
| May 16, 2025 | JBIO Jade Biosciences, Inc. | POpen-market purchase Common Stock | +6,000 | $7.40 | $44k | 6,000 | May 19, 2025 |
Questions about Tom Frohlich
Answered from the filings on this page, as of the latest one.
Is Tom Frohlich buying or selling?
Not in the last 12 months. Tom Frohlich's latest open-market trade on SEC Form 4 was bought $44k of JBIO on May 16, 2025.
How did Tom Frohlich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Tom Frohlich has 0.
Where does Tom Frohlich file Form 4?
Tom Frohlich has filed Form 4 at JBIO (Jade Biosciences, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.